Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372580 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL8191842 | 0.91 | ALDH1A1 (0.83) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL8196041 | 0.91 | ALDH1A1 (0.83) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL8193560 | 0.87 | KDM4E (0.77) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL8196979 | 0.87 | KDM4E (0.77) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL8183859 | 0.86 | ALDH1A1 (0.76) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL8195859 | 0.86 | ALDH1A1 (0.76) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL2455779 | 0.86 | ALDH1A1 (0.76) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL8313781 | 0.86 | KDM4E (0.76) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 | |
| SCHEMBL8192928 | 0.85 | ALDH1A1 (0.74) | ALDH1A1CYP1A2CYP3A4HSD17B10CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| US-20090136463-A1 | Schwann Cell Bridge Implants and Phosphodiesterase Inhibitors to Stimulate CNS Nerve Regeneration | UNIVERSITY OF MIAMI (US) | 2009-05-28 | — | — | US | claimed |
| EP-1482916-A4 | SCHWANN CELL AND PHOSPHODIESTERASE INHIBITORS BASED THERAPY | UNIV MIAMI (US) | 2007-12-12 | — | — | EP | claimed |
| EP-1482916-A2 | SCHWANN CELL AND PHOSPHODIESTERASE INHIBITORS BASED THERAPY | University of Miami (US) | 2004-12-08 | — | — | EP | claimed |
| US-20030220280-A1 | Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration | BUNGE MARY BARTLETT (US) | 2003-11-27 | — | — | US | claimed |
| WO-2003065994-A2 | SCHWANN CELL AND PHOSPHODIESTERASE INHIBITORS BASED THERAPY | UNIVERSITY OF MIAMI (US) | 2003-08-14 | — | — | WO | claimed |
| US-6136810-A | DRUGS AS ENZYME INHIBITORS OF PHOSPHODIESTERASE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | claimed |
| EP-0885894-A1 | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-23 | — | — | EP | claimed |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| EP-3984555-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-20210154177-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-27 | — | — | US | disclosed |
| US-20210145803-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2021-05-20 | — | — | US | disclosed |
| US-10940140-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2021-03-09 | — | — | US | disclosed |
| WO-2004047817-A1 | PDE4 AND PDE3/4 INHIBITORS FOR USE IN THE TREATMENT OF CACHEXIA | ALTANA PHARMA AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| US-20030220280-A1 | Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration | BUNGE MARY BARTLETT (US) | 2003-11-27 | — | — | US | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-6136810-A | DRUGS AS ENZYME INHIBITORS OF PHOSPHODIESTERASE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| EP-0885894-A1 | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | ALDH1A1 3155/4885CYP1A2 4566/4885CYP3A4 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.